The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo

Rare and potent monoclonal antibodies (mAbs) against the Plasmodium falciparum (Pf) circumsporozoite protein (CSP) on infective sporozoites (SPZ) preferentially bind the PfCSP junctional tetrapeptide NPDP or NVDP minor repeats while cross-reacting with NANP central repeats in vitro. The extent to wh...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yevel Flores-Garcia, Lawrence T. Wang, Minah Park, Beejan Asady, Azza H. Idris, Neville K. Kisalu, Christian Muñoz, Lais S. Pereira, Joseph R. Francica, Robert A. Seder, Fidel Zavala
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Acceso en línea:https://doaj.org/article/111b6dad7a6b41a189095f7767ef2b17
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:111b6dad7a6b41a189095f7767ef2b17
record_format dspace
spelling oai:doaj.org-article:111b6dad7a6b41a189095f7767ef2b172021-11-25T05:47:33ZThe P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo1553-73661553-7374https://doaj.org/article/111b6dad7a6b41a189095f7767ef2b172021-11-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601602/?tool=EBIhttps://doaj.org/toc/1553-7366https://doaj.org/toc/1553-7374Rare and potent monoclonal antibodies (mAbs) against the Plasmodium falciparum (Pf) circumsporozoite protein (CSP) on infective sporozoites (SPZ) preferentially bind the PfCSP junctional tetrapeptide NPDP or NVDP minor repeats while cross-reacting with NANP central repeats in vitro. The extent to which each of these epitopes is required for protection in vivo is unknown. Here, we assessed whether junction-, minor repeat- and central repeat-preferring human mAbs (CIS43, L9 and 317 respectively) bound and protected against in vivo challenge with transgenic P. berghei (Pb) SPZ expressing either PfCSP with the junction and minor repeats knocked out (KO), or PbCSP with the junction and minor repeats knocked in (KI). In vivo protection studies showed that the junction and minor repeats are necessary and sufficient for CIS43 and L9 to neutralize KO and KI SPZ, respectively. In contrast, 317 required major repeats for in vivo protection. These data establish that human mAbs can prevent malaria infection by targeting three different protective epitopes (NPDP, NVDP, NANP) in the PfCSP repeat region. This report will inform vaccine development and the use of mAbs to passively prevent malaria. Author summary Human monoclonal antibodies are a promising approach for preventing malaria. Highly potent human antibodies show preferential binding to the junction or minor repeat regions of the circumsporozoite protein (CSP) of P. falciparum and cross-react to repetitive (NANP) repeats. The requirement for these binding sites for mediating protection in vivo remains unknown. Here, using transgenic P. berghei parasites expressing PfCSP containing deletions of these junctional or minor epitopes, or PbCSP containing additions of these PfCSP epitopes, we demonstrate these epitopes are necessary and sufficient to mediate protection and don’t require cross-reactivity to the NANP repeats. Our findings establish a mechanism of antibody mediated protection in vivo to prevent malaria and provide the rationale for multi-epitope vaccines to increase the breadth of the antibody responses.Yevel Flores-GarciaLawrence T. WangMinah ParkBeejan AsadyAzza H. IdrisNeville K. KisaluChristian MuñozLais S. PereiraJoseph R. FrancicaRobert A. SederFidel ZavalaPublic Library of Science (PLoS)articleImmunologic diseases. AllergyRC581-607Biology (General)QH301-705.5ENPLoS Pathogens, Vol 17, Iss 11 (2021)
institution DOAJ
collection DOAJ
language EN
topic Immunologic diseases. Allergy
RC581-607
Biology (General)
QH301-705.5
spellingShingle Immunologic diseases. Allergy
RC581-607
Biology (General)
QH301-705.5
Yevel Flores-Garcia
Lawrence T. Wang
Minah Park
Beejan Asady
Azza H. Idris
Neville K. Kisalu
Christian Muñoz
Lais S. Pereira
Joseph R. Francica
Robert A. Seder
Fidel Zavala
The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo
description Rare and potent monoclonal antibodies (mAbs) against the Plasmodium falciparum (Pf) circumsporozoite protein (CSP) on infective sporozoites (SPZ) preferentially bind the PfCSP junctional tetrapeptide NPDP or NVDP minor repeats while cross-reacting with NANP central repeats in vitro. The extent to which each of these epitopes is required for protection in vivo is unknown. Here, we assessed whether junction-, minor repeat- and central repeat-preferring human mAbs (CIS43, L9 and 317 respectively) bound and protected against in vivo challenge with transgenic P. berghei (Pb) SPZ expressing either PfCSP with the junction and minor repeats knocked out (KO), or PbCSP with the junction and minor repeats knocked in (KI). In vivo protection studies showed that the junction and minor repeats are necessary and sufficient for CIS43 and L9 to neutralize KO and KI SPZ, respectively. In contrast, 317 required major repeats for in vivo protection. These data establish that human mAbs can prevent malaria infection by targeting three different protective epitopes (NPDP, NVDP, NANP) in the PfCSP repeat region. This report will inform vaccine development and the use of mAbs to passively prevent malaria. Author summary Human monoclonal antibodies are a promising approach for preventing malaria. Highly potent human antibodies show preferential binding to the junction or minor repeat regions of the circumsporozoite protein (CSP) of P. falciparum and cross-react to repetitive (NANP) repeats. The requirement for these binding sites for mediating protection in vivo remains unknown. Here, using transgenic P. berghei parasites expressing PfCSP containing deletions of these junctional or minor epitopes, or PbCSP containing additions of these PfCSP epitopes, we demonstrate these epitopes are necessary and sufficient to mediate protection and don’t require cross-reactivity to the NANP repeats. Our findings establish a mechanism of antibody mediated protection in vivo to prevent malaria and provide the rationale for multi-epitope vaccines to increase the breadth of the antibody responses.
format article
author Yevel Flores-Garcia
Lawrence T. Wang
Minah Park
Beejan Asady
Azza H. Idris
Neville K. Kisalu
Christian Muñoz
Lais S. Pereira
Joseph R. Francica
Robert A. Seder
Fidel Zavala
author_facet Yevel Flores-Garcia
Lawrence T. Wang
Minah Park
Beejan Asady
Azza H. Idris
Neville K. Kisalu
Christian Muñoz
Lais S. Pereira
Joseph R. Francica
Robert A. Seder
Fidel Zavala
author_sort Yevel Flores-Garcia
title The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo
title_short The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo
title_full The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo
title_fullStr The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo
title_full_unstemmed The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo
title_sort p. falciparum csp repeat region contains three distinct epitopes required for protection by antibodies in vivo
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/111b6dad7a6b41a189095f7767ef2b17
work_keys_str_mv AT yevelfloresgarcia thepfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT lawrencetwang thepfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT minahpark thepfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT beejanasady thepfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT azzahidris thepfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT nevillekkisalu thepfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT christianmunoz thepfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT laisspereira thepfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT josephrfrancica thepfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT robertaseder thepfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT fidelzavala thepfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT yevelfloresgarcia pfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT lawrencetwang pfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT minahpark pfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT beejanasady pfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT azzahidris pfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT nevillekkisalu pfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT christianmunoz pfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT laisspereira pfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT josephrfrancica pfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT robertaseder pfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
AT fidelzavala pfalciparumcsprepeatregioncontainsthreedistinctepitopesrequiredforprotectionbyantibodiesinvivo
_version_ 1718414444067815424